Cell clinical trials

Understanding kidney cancer genes in families

This research study helps doctors understand inherited kidney cancers and related conditions that run in families. Researchers collect medical information and blood samples to identify genetic causes and improve how these conditions are diagnosed and treated.

Study of blood cancers’ natural course and next treatment needs

This study follows people with certain slow-growing blood cancers (CLL/SLL, LPL/WM, and related conditions) to understand how they progress and what leads to needing treatment. It may help doctors predict changes over time and plan care more effectively.

Harvesting Cancer Cells for Experimental Treatment

This trial collects immune cells from cancer patients or healthy volunteers to develop new experimental cancer treatments. Researchers will take a sample of your tumor or blood cells, grow them in the lab, and study how to use them to fight your cancer.

Study of thyroid lumps and thyroid cancer

This study looks at people who have or may have thyroid nodules (lumps in the thyroid gland in your neck) or thyroid cancer, as well as family members who may have inherited a higher risk. It aims to better understand and diagnose these thyroid problems.

Evaluation of a Point-of-Care, AI-Powered Spectroscopy Device for Triage of Suspicious Vulvar Lesions: A Pilot Study

BEX101 for B-cell non-Hodgkin's lymphoma

This trial tests a new treatment called BEX101 for people with certain types of B-cell lymphoma that have come back or not responded to standard treatments. It aims to see if this therapy can help shrink or control the cancer.

A study of a new drug for advanced solid tumors

This trial tests a new drug called petosemtamab (MCLA-158) for people with advanced solid tumors that have not responded to other treatments. The drug is designed to target and kill cancer cells. You may be able to participate if you meet the health and cancer history requirements.

Follow-on treatment study for dabrafenib and trametinib

This study lets people who finished a prior dabrafenib/trametinib trial (sponsored by Novartis or former GSK) continue those medicines if the study doctor thinks it will help. It mainly focuses on ongoing treatment benefit rather than testing a new drug.

Study of a new drug for relapsed small cell lung cancer

This study tests a new drug (GSK5764227) for people whose extensive-stage small cell lung cancer has gotten worse after platinum chemotherapy combined with immunotherapy. The goal is to see if this targeted treatment can help shrink tumors and control the cancer.

A study of CLN-978 for rheumatoid arthritis

This trial tests a new medicine called CLN-978, given as an injection under the skin, to see if it can help people with active rheumatoid arthritis who haven't improved enough with other treatments. CLN-978 works by targeting a specific immune cell to reduce inflammation.

Study of QXL138AM for advanced solid tumors and multiple myeloma

This trial tests an investigational drug called QXL138AM for people with advanced solid tumors or multiple myeloma that has not responded to standard treatments. The goal is to see if the drug is safe and effective.

Blood test study during prostate surgery for localized prostate cancer

This trial studies prostate cancer cells in the blood (“circulating tumor cells”) while you undergo planned prostate surgery. It may help doctors better understand prostate cancer and how it behaves early, which could guide future treatment decisions.

Personalized T cell therapy for blood cancers

This trial tests a treatment that takes your own immune cells, modifies them to attack cancer cells, and gives them back to you. It is for people with certain blood cancers who have specific gene changes.

MyeloMATCH screening to match you to AML or MDS treatment

This study screens people with newly suspected acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) to see which treatment approach fits best—either a specific study treatment or standard care. It may help by directing you to the right option and by sharing your blood/bone marrow samples for research.

Hearing and balance side effects of cisplatin in head and neck cancer

This study looks at how cisplatin chemotherapy affects hearing and balance in people with head and neck cancer. It compares patients who get cisplatin with those who only get radiation, to understand and possibly reduce these side effects.

A new drug for solid cancers that did not respond to usual care

This early-stage (Phase 1) trial tests AOH1996 in adults with solid tumors that have stopped responding to standard treatments. It’s meant to find a safe dose and see if the drug can help, especially in cancers with limited options.

Gene therapy for solid tumors that returned after treatment

This trial tests a new type of gene therapy that uses your own immune cells (called myeloid cells) engineered to produce a protein (IL-12) to fight your cancer. It is for people with solid tumors that have not responded to standard treatments.

Study of pembrolizumab plus calderasib for KRAS G12C lung cancer after surgery

This trial tests a combination of two drugs (pembrolizumab and calderasib) after surgery for people with a specific type of lung cancer gene mutation called KRAS G12C. It aims to see if this therapy can help prevent the cancer from coming back.

Belinostat trial for neuroendocrine cancer based on genetics

This trial tests a drug called belinostat, possibly combined with other drugs, based on your genetic makeup. It aims to find the right dose for people with a rare and aggressive neuroendocrine cancer that started outside the lungs.

Imaging HER2 in advanced lung cancer with a special PET scan

This study tests an imaging technique that uses a special tracer to attach to HER2 (a protein on some cancer cells) and make it visible on a PET/CT scan. The goal is to see if the tracer can help doctors understand where HER2 is in the body, which may guide future treatment options for advanced lung cancer.

Olutasidenib for IDH1-mutated blood cancers after transplant

This trial tests a drug called olutasidenib for people with certain blood cancers (AML, MDS, or CMML) that have a specific IDH1 gene change. The goal is to see if it can help prevent relapse after a donor stem cell transplant.

Study of telisotuzumab adizutecan plus immunotherapy for advanced lung cancer

This trial tests a new combination treatment for people with advanced non-squamous non-small cell lung cancer who haven't received prior therapy for advanced disease and don't have specific gene changes. The treatment includes an antibody-drug conjugate (telisotuzumab adizutecan) plus an immunotherapy drug (PD-1 checkpoint inhibitor) to see if it helps shrink tumors and improve outcomes.

Preventing graft-versus-host disease in children after stem cell transplant

This study tests a combination of three drugs (cyclophosphamide, sirolimus, and VIC-1911) to prevent graft-versus-host disease (GVHD), a common complication after a stem cell transplant. It is for children aged 8-18 with certain blood diseases who are undergoing a haploidentical stem cell transplant.

Stem cell transplant for late-stage age-related macular degeneration

This trial tests a new treatment for advanced age-related macular degeneration (AMD) where doctors transplant lab-grown retinal cells (from stem cells) under the retina to try to replace damaged cells and improve or preserve vision. It is for people with severe vision loss from either dry AMD (large area of dead tissue) or old wet AMD that has stopped leaking.